THE
TRITON-CM
STUDY
TRITON-CM is a phase 3, global, randomized, double‑blind, placebo-controlled study to evaluate the efficacy and safety of nucresiran in patients with ATTR amyloidosis with cardiomyopathy.
HCP Page
Study objectives
The primary objective of the study is to evaluate the efficacy of nucresiran, administered subcutaneously, twice yearly, compared to placebo in reducing all-cause mortality and cardiovascular (CV) events in patients with ATTR amyloidosis with cardiomyopathy.
Secondary objectives of the study are to evaluate the efficacy of nucresiran compared with placebo on delaying time to first CV event or all-cause mortality, reducing all-cause mortality, reducing CV events, and improving health-related quality of life.
TRITON-CM
is an event-driven study that will last between 5 and 8 years.
This time period will include:
A Screening Period
Up to 45 days
A Double-Blind Treatment Period
2-5 years
Length of the Double-Blind Treatment Period will be determined by the number of CV events such as hospitalizations and urgent heart-failure visits.An optional Open-Label Extension Period
2 years
A Follow-up Period
12 months
(24 months for individuals of childbearing potential)
are permissible throughout all study periods.
